Organization of the Company We are a specialist medical diagnostics company focused primarily on the research, development and manufacture of in vitro diagnostic test devices for consumer and professional point-of-care use. In addition, we own, manage and operate a hemostasis laboratory. Key aspects of our strategy for increasing shareholder value include:  executing on our business activities, including undertaking research and development activities, manufacturing products and providing development and support services including providing laboratory services;  extending and demonstrating the broader application of our technology and seeking to enter into collaborative, strategic or distribution arrangements with other life sciences companies or other industry participants with respect to specific tests or specific fields;  participating in healthcare markets across the globe; and  identifying and pursuing related opportunities for growth. Our plan of operations over the remainder of the fiscal year ending December 2019 is to:  seek to enter into collaborative, strategic or distribution arrangements with other life sciences companies or other industry participants with respect to the development and commercialization of specific tests or specific fields;  manufacture products;  undertake research and development work;  provide the necessary post-market support for our customers and partners;  provide laboratory services for our customers and partners;  demonstrate the broader application of our technology platform for markets with significant commercial potential; and  identify, investigate and evaluate inorganic growth opportunities within the overall strategic initiatives. We have rights to an extensive patent portfolio, with certain patents owned by UBS and a number licensed to UBS by LifeScan and other third-party licensors. The Companys first global strategic partnership was established with LifeScan with respect to diabetes care. The Company developed a blood glucose product with LifeScan (OneTouch Verio  ). During 2018, LifeScan gave notice and exercised its right to convert its obligation to pay quarterly service fees to UBS (the LifeScan Conversion). Accordingly, we have not received any further quarterly service fees beyond 2018 and we do not expect to receive any further revenues from LifeScan unless we enter into a new agreement with LifeScan in the future. In October 2018, Platinum Equity acquired LifeScan, Inc. from Johnson &amp; Johnson. Unless otherwise noted, references to LifeScan in this document are references collectively or individually to LifeScan, Inc., and/or LifeScan Europe, a division of Cilag GmbH International. We have, worked with Siemens Healthcare Diagnostics, Inc. (Siemens) since 2012 in relation to a range of products for the point-of-care coagulation testing market, pursuant to a collaboration agreement with Siemens (the Collaboration Agreement). The first such product developed with Siemens, the Xprecia Stride  Coagulation Analyzer, received CE mark approval on December 9, 2014 and US Food and Drug Administration (FDA) approval on October 4, 2016. The Xprecia Stride  Coagulation Analyzer is now available in the United States, Europe, the Middle East, Africa, Asia Pacific, Latin America and Canada. Under the terms of a supply agreement with Siemens (the Supply Agreement), UBS is the manufacturer of test strips for this product for Siemens. The Collaboration Agreement was terminated on September 18, 2019. On September 9, 2019, we entered into certain binding term sheets with Siemens (the Siemens Term Sheets) and on September 18, 2019, we entered into a commercial and distribution agreement with Siemens (the Siemens Distribution Agreement) and a supply agreement with Siemens (the Siemens Supply Agreement and together with the Siemens Term Sheets and the Siemens Distribution Agreement the 2019 Siemens Agreements). Pursuant to the 2019 Siemens Agreements the Company agreed to acquire certain assets of Siemens (the Siemens Acquisition). Pursuant to the terms of the 2019 Siemens Agreements, among other things:  Siemens has committed to order a certain minimum amount of Xprecia Stride  strips from UBI over the subsequent 42 months, subject to certain conditions; and  The Company has the right to pursue partnership and distribution opportunities for point-of-care coagulation products outside of our arrangement with Siemens, which we believe will allow us to access new global markets and market segments, including the hospital point-of-care segment that was previously exclusive to Siemens under the Siemens Collaboration Agreement. The Company intends to undertake an open market (or on-market) buyback of up to 10% of its outstanding equity securities over the 12 months following October 14, 2019 (the Buyback). Any securities purchased pursuant to the Buyback would be purchased at the Companys sole discretion and funded from existing cash reserves. The Company would only buy back securities at such times and in such circumstances as the Company considers beneficial to the efficient capital management of the Company. The Buyback and the terms thereof are dependent upon market conditions, volumes and other relevant factors and there is no assurance that the Company will undertake the Buyback or purchase any of its outstanding equity securities pursuant to the Buyback.